167 related articles for article (PubMed ID: 38342727)
1. Geographic and Racial Disparities in Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials Access for Diffuse Large B-Cell Lymphoma.
Shahzad M; Khalid MF; Amin MK; Basharat A; Ammad-Ud-Din M; Park R; Anwar I; Faisal MS; Jaglal M
Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):316-322. PubMed ID: 38342727
[TBL] [Abstract][Full Text] [Related]
2. Geographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple Myeloma.
Alqazaqi R; Schinke C; Thanendrarajan S; Zangari M; Shaughnessy J; Zhan F; Tricot G; van Rhee F; Al Hadidi S
JAMA Netw Open; 2022 Aug; 5(8):e2228877. PubMed ID: 36018590
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Doraiswamy A; Shah MR; Bannerji R
Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
[TBL] [Abstract][Full Text] [Related]
4. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
[TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update.
Lakshman A; Kumar SK
Am J Hematol; 2022 Jan; 97(1):99-118. PubMed ID: 34661922
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
[TBL] [Abstract][Full Text] [Related]
7. CAR T cell therapy for B-cell lymphomas.
Chavez JC; Locke FL
Best Pract Res Clin Haematol; 2018 Jun; 31(2):135-146. PubMed ID: 29909914
[TBL] [Abstract][Full Text] [Related]
8. Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy Access.
Ahmed N; Shahzad M; Shippey E; Bansal R; Mushtaq MU; Mahmoudjafari Z; Faisal MS; Hoffmann M; Abdallah AO; Divine C; Hamadani M; McGuirk J; Shune L
Transplant Cell Ther; 2022 Jul; 28(7):358-364. PubMed ID: 35429662
[TBL] [Abstract][Full Text] [Related]
9. Chimeric Antigen Receptor-Engineered T-Cells - A New Way and Era for Lymphoma Treatment.
Mihăilă RG
Recent Pat Anticancer Drug Discov; 2019; 14(4):312-323. PubMed ID: 31642414
[TBL] [Abstract][Full Text] [Related]
10. Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms.
Al Hadidi S; Schinke C; Thanendrarajan S; Zangari M; van Rhee F
JAMA Netw Open; 2022 Apr; 5(4):e228161. PubMed ID: 35442451
[TBL] [Abstract][Full Text] [Related]
11. Relapsed or refractory large B-cell lymphoma after chimeric antigen receptor T-cell therapy: Current challenges and therapeutic options.
Del Toro-Mijares R; Oluwole O; Jayani RV; Kassim AA; Savani BN; Dholaria B
Br J Haematol; 2023 Apr; 201(1):15-24. PubMed ID: 36709623
[TBL] [Abstract][Full Text] [Related]
12. Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes.
Liu J; Yang S; Cao B; Zhou G; Zhang F; Wang Y; Wang R; Zhu L; Meng Y; Hu C; Liang H; Lin X; Zhu K; Chen G; Luo KQ; Di L; Zhao Q
J Hematol Oncol; 2021 Jan; 14(1):21. PubMed ID: 33514401
[TBL] [Abstract][Full Text] [Related]
13. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
[TBL] [Abstract][Full Text] [Related]
14. Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas.
Major A; Kamdar M
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):370-381. PubMed ID: 38066907
[TBL] [Abstract][Full Text] [Related]
15. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
16. Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas.
Trabolsi A; Arumov A; Schatz JH
Blood Cancer J; 2024 Feb; 14(1):27. PubMed ID: 38331870
[TBL] [Abstract][Full Text] [Related]
17. Access to Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma.
Snyder S; Chung KC; Jun MP; Gitlin M
Adv Ther; 2021 Sep; 38(9):4659-4674. PubMed ID: 34302277
[TBL] [Abstract][Full Text] [Related]
18. CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies.
Liang Y; Liu H; Lu Z; Lei W; Zhang C; Li P; Liang A; Young KH; Qian W
J Hematol Oncol; 2021 Feb; 14(1):26. PubMed ID: 33593414
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor T cell therapy for non-Hodgkin lymphoma.
Ghobadi A
Curr Res Transl Med; 2018 May; 66(2):43-49. PubMed ID: 29655961
[TBL] [Abstract][Full Text] [Related]
20. Health Care Resource Utilization and Total Costs of Care Among Patients with Diffuse Large B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy in the United States.
Keating SJ; Gu T; Jun MP; McBride A
Transplant Cell Ther; 2022 Jul; 28(7):404.e1-404.e6. PubMed ID: 35354101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
